Could a safer sedative shield kidneys during major abdominal surgery?
NCT ID NCT07674719
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial compares two sedatives—remimazolam and propofol—given during liver or pancreas surgery to see which better prevents acute kidney injury after the operation. The study includes adults aged 19 to 85 scheduled for elective hepatobiliary-pancreatic surgery. Researchers aim to find out if remimazolam helps maintain stable blood pressure and reduces kidney damage, especially when fluid intake is limited during surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remimazolam
What this could lead to
If remimazolam proves better at protecting kidney function, it could become a preferred sedative for surgeries where fluid intake is limited.
What could go wrong
This is a small, early-stage trial with only 78 participants, so results may not apply broadly. Remimazolam may not reduce kidney injury more than propofol.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••